Reagents and conditions: (a) 95% TFA, 2.5% TIS, 2.5% H2O, 2h, rt; (b) CBL--354, DiPEA, DMF, 16h, rt; (c) azobenzene, HBTU, HOBt, DiPEA, DMF, 16h, rt; (d) alkyne 6, tBuOH, H2O, CuSO4, sodium ascorbate, 16h, 37°C; (e) Lev--OSu, DiPEA, DMF, 16h, rt. Similar probes were synthesized without spacer, with an aminohexanoic acid spacer or with the described PEG spacer (synthesis not shown). These probes were sortagged onto ubiquitin and the resulting cleavable linker containing ubiquitin derivatives were used in a pulldown experiment (SI Fig 1A) . The ubiquitin was incubated with streptavidin--agarose and subsequently washed to remove any unbound ubiquitin. Next, the resin was treated with hydrazine to initiate cleavage.
The eluted product was loaded on gel and blotted using an anti--ubiquitin antibody (top panel SI Fig 1A) . Boiling in sample buffer eluted the material remaining of the streptavidin--sepharose beads and the resulting material was also run on SDS--PAGE (lower panels SI Fig 1A) . These experiments revealed that 80% of Biotin--PEG--ubiquitin eluted after 5h, whereas the Biotin--ubiquitin construct and the Biotin--Ahx--ubiquitin construct only showed 50% cleavage. We therefore decided to add an PEG spacer to all the different biotin--[cleavable--linker]--UbVME probes. We transacylated peptides 1-3 onto G3UbVME as described in the main manuscript.
Purification of the resulting product by reverse phase HPLC was followed by LC/MS analysis of the products (SI Fig 1B) and we subsequently analyzed the purity of products by SDS--PAGE (SI Fig 1C) .
of Cleavable linker containing UbVME by (B) mass-spectrometry and (C) gel electrophoresis.
General experimental.
All chemicals were of commercial sources and were used as received. Fmoc--Gly--OH, --benzotriazole--N,N,N',N'--tetramethyl--uronium hexafluorophosphate (HBTU) , benzotriazol--1--yl oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) were purchased from
EMD Biosciences/Novabiochem. Rink amide resin was purchased from Advanced Chemtech. (E)--4--((5--(2--azidoethyl)--2--hydroxyphenyl)diazenyl)benzoic acid was synthesized as described by Hang and co--workers. [32] Bisaryl hydrazone linker (Chromalink TM biotin labeling reagent) was purchased from solulink. Levulinoyl cleavable linker was a generous gift from the Overkleeft lab.
Water used in biological procedures or as a reaction solvent was purified using a MilliQ purification system (Millipore). DriSolv® anhydrous CH2Cl2, DriSolv® anhydrous MeOH, DriSolv® anhydrous DMF were purchased from EMD Chemicals. HPLC/FPLC. HPLC purifications were achieved using an Agilent 1100 Series HPLC system equipped with a Waters Delta Pak 15 μm, 100 Å C18 column (7.8 x 300 mm, MeCN:H2O gradient mobile phase, 3 mL/min) using the gradient indicated below.
Cation exchange chromatography was performed on a Pharmacia AKTA Purifier system equipped with a Mono S 5/50 GL column (Amersham).
UV-vis Spectrocopy. UV--vis spectroscopy was performed on a Nanodrop ND--1000 spectrophotometer (Thermo Scientific, USA).
General procedure for the solid phase peptide synthesis of the probes.
Rink--amide resin was solvated in NMP and after removal of the Fmoc--group by treating the resin with 20% piperidine in NMP, the resin was loaded and elongated using the consecutive steps. (I) The resin was washed with NMP (3x), CH2Cl2 (3x) and NMP. (II) Fmoc--protected amino acids were condensed under the agency of HOBt (3 equiv.), PyBOP (3 equiv.) and DiPEA (6 equiv.). (III) The resin was washed again using the same conditions as in step (I). (IV) The coupling was monitored using Kaiser test and if complete, (V) the Fmoc--protective group was removed using 20% piperidine in NMP.
In the final step, the peptides were cleaved off resin by agitating the resin in the presence 95%TFA, 2.5% TIS, 2.5% H2O for 3h. Ice--cold Et2O was added to the cleavage solution and the formed precipitate was collected by centrifugation of the solution for 30 min at 4°C. The crude pellet was purified by reverse phase HPLC purification (buffers used: A: H2O, B: ACN, C: 10% TFA in H2O).
Biotin-PEG(15)-alkyne
Glutaric acid propargylamide 7(89 mg, 0.525 mmol) was dissolved in DMF (2.5 mL). 
Biotin-Lev-LPETGG-CONH2 (3)
H2N--Leu--Pro--Arg--Thr--Gly--Gly--CONH2 (10 mg, 16.8 µmol), synthesized according the general procedure, was dissolved in CH2Cl2 (250 µL). 4--(3--((2,5--dioxopyrrolidin--1--yl)oxy)--3--oxopropyl)--2,6--diisopropylphenyl 7--azido--4--oxoheptanoate (6.5 mg, 12.6 µmol) and N,N--diisopropylethylamine (13 µL, 74.6 µmol) were added. When LC/MS showed complete conversion, the reaction was concentrated in vacuo, redissolved in DMF and Biotin--PEG--alkyne 4 (18 mg, 30 µmol), CuSO4 (20 µL, 1M in H2O) and sodium ascorbate (30 µL, 1M in H2O) were added. After incubating overnight at 37°C, the product was purified by RP--HPLC (25--40% B in 20 min (5 CV)) gave the title compound 3 (8.0 mg, 5.7 µmol, 34%) as a white solid. 
